Regeneron Pharmaceuticals Inc (REGN)
Health Care ยท Pharmaceutical Preparations
Regeneron Pharmaceuticals Inc (REGN) is listed on Nasdaq, where its shares have traded since April 2, 1991. SentiSense covers Regeneron Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Leonard Schleifer is its chief executive officer. The company reports 15,410 employees, and its corporate website is www.regeneron.com.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 1,313 institutions reported holding REGN, with 90.2 million shares worth $56.4 billion in aggregate. The largest reported holders were Vanguard, BlackRock and Dodge & Cox. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on REGN
- REGN sentiment: whether news and social coverage of Regeneron Pharmaceuticals Inc leans bullish or bearish, and the stories driving it.
- REGN ownership: all 1,313 reporting institutions, plus insider and congressional trades.
- REGN financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Regeneron Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Regeneron Pharmaceuticals Inc do?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.
What sector is REGN in?
SentiSense classifies Regeneron Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does REGN stock trade?
Regeneron Pharmaceuticals Inc (REGN) is listed on Nasdaq, where its shares have traded since April 2, 1991.
Who is the CEO of Regeneron Pharmaceuticals Inc?
Leonard Schleifer is the chief executive officer of Regeneron Pharmaceuticals Inc.